Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | F11 | P03951 | 2/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3690091 | 0.87 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL31547133 | 0.85 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL14217299 | 0.84 | LPL (0.50) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL189992 | 0.84 | LPL (0.50) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL30993446 | 0.84 | LPL (0.50) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL31531362 | 0.83 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL57994 | 0.83 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL14059947 | 0.82 | ESR2 (0.43) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16105038 | 0.81 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19414434 | 0.81 | LPL (0.47) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507262-B2 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY (US) | 2009-03-24 | — | — | US | claimed |
| EP-2018146-A2 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | The Procter and Gamble Company (US) | 2009-01-28 | — | — | EP | claimed |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY | 2007-09-13 | — | — | US | claimed |
| WO-2007102126-A2 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2007-09-13 | — | — | WO | claimed |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12612368-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-12091413-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4146348-B1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240174648-A1 | Small Molecule Compound | TECHNODERMA MEDICINES INC. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | disclosed |
| WO-2005074603-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | LPL 4606/4885LIPG 4551/4885CA1 4808/4885 |
| US-12091413-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | LPL 4300/4885LIPG 3916/4885CA1 4765/4885 |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | LPL 927/4885LIPG 1684/4885CA1 4127/4885 |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | LPL 4580/4885LIPG 3886/4885CA1 1132/4885 |
| US-20240174648-A1 | Small Molecule Compound | JAK1, JAK2, TYK2 | LPL 4884/4885LIPG 4853/4885CA1 3512/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | LPL 1593/4885LIPG 809/4885CA1 31/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | LPL 306/4885LIPG 341/4885CA1 2331/4885 |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | KRT18, AKR7A2, AKR1C4 | LPL 3490/4885LIPG 3289/4885CA1 1171/4885 |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | LPL 4300/4885LIPG 3916/4885CA1 4765/4885 |
| US-12612368-B2 | Cancer treatments targeting cancer stem cells | MALT1, BCOR, MCL1 | LPL 1570/4885LIPG 935/4885CA1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.